Safety and Efficacy of the Addition of Lapatinib to Perioperative Chemotherapy for Resectable HER2-Positive Gastroesophageal Adenocarcinoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
JAMA Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Safety and Efficacy of the Addition of Lapatinib to Perioperative Chemotherapy for Resectable HER2-Positive Gastroesophageal Adenocarcinoma: A Randomized Phase 2 Clinical Trial
JAMA Oncol 2019 Jun 20;[EPub Ahead of Print], EC Smyth, S Rowley, FH Cafferty, W Allum, HI Grabsch, S Stenning, A Wotherspoon, D Alderson, T Crosby, W Mansoor, JS Waters, H Neville-Webbe, S Darby, J Dent, M Seymour, J Thompson, S Sothi, J Blazeby, RE Langley, D CunninghamFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.